Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: Case report and review of the literature

详细信息    查看全文

• 作者：Michel van Kruchten ; Geke A.P. Hospers ; Andor W.J.M. Glaudemans ; Harry Hollema ; Henri毛tte J.G. Arts ; Anna K.L. Reyners
• 关键词：Endometrial stromal sarcoma ; Oestrogen receptor ; Endocrine therapy ; Fulvestrant ; FES PET
• 刊名：European Journal of Cancer
• 出版年：December, 2013
• 年：2013
• 卷：49
• 期：18
• 页码：3850-3855
• 全文大小：1534 K

文摘

Although the majority of endometrial stromal sarcomas (ESSs) express oestrogen receptor (ER), data on the efficacy of ER-targeted therapies are scarce. Using PubMed search engine we identified nine case reports and small series in a total of 25 patients reporting on the efficacy of palliative ER-targeted therapies. Literature supports the efficacy of aromatase inhibitors after the failure of progestins, but not of the partial ER-antagonist tamoxifen. Fulvestrant is a pure ER-antagonist with a distinct mechanism, of which efficacy has not yet been reported in ESS. We present a patient that underwent positron emission tomography and computed tomography (PET/CT) of ER-expression with the tracer ¹⁸F-fluoroestradiol (FES). High levels of ER-expression provided a rationale for fulvestrant therapy. FES-PET/CT was repeated after 6 months and indicated a strong decrease in tumour FES-uptake, and 15% reduction in tumour diameters according to Response Evaluation Criteria in Solid Tumours (RECIST) criteria.